Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: Role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase

Anti-Cancer Drugs

Volumn 21, Issue 6, 2010, Pages 591-599

  Sigmond, Jennifer ^a   Bergman, Andries M ^a   Leon, Leticia G ^a   Loves, Willem J P ^a   Hoebe, Eveline K ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Deoxycytidine kinase activity; Gemcitabine; Multidrug resistance; Protein kinase C; Ribonucleotide reductase; Staurosporine; Thymidine kinase 2 activity

Indexed keywords

DEOXYCYTIDINE KINASE; GEMCITABINE; PROTEIN KINASE C; RIBONUCLEOTIDE REDUCTASE; STAUROSPORINE; THYMIDINE KINASE; THYMIDINE KINASE 2; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL CYCLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE C; RIBONUCLEOTIDE REDUCTASES; STAUROSPORINE;

EID: 77953538465     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833a3543     Document Type: Article

References (54)

1. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB. Evaluation of the antitumor activity of a (20,20-difluoro-20-deoxycytidine). Cancer Res 1990; 50:4417-4422.
2. Braakhuis BJM, Ruiz van Haperen VWT, Boven E, Veerman G, Peters GJ. Schedule-dependent antitumor effect of gemcitabine in in vivo systems. Semin Oncol 1995; 22:42-46.
3. Abratt RP, Bezwoda W, Falkson G, Goedhals L, Hacking D. Efficacy and safety profile of gemcitabine in non-small cell lung cancer. Phase II study. J Clin Oncol 1994; 12:1535-1540.
4. Bergman AM, Pinedo HM, Jongsma APM, Brouwer M, Ruiz van Haperen VWT, Veerman G, et al. Decreased resistance to gemcitabine of cytosine arabinoside resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem Pharm 1999; 57:397-406.
5. Wang J, Choudhury D, Chattopadhyaya J, Eriksson S. Stereoisomeric selectivity of human deoxyribonucleoside kinases. Biochemistry 1999; 38:16993-16999.
6. Ruiz van Haperen VWT, Veerman G, Vermorken JB, Peters GJ. 20,20-Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines. Biochem Pharmacol 1993; 46:762-766.
7. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 20,20-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51:6110-6117.
8. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 20,20 - difluorodeoxycytidine. Mol Pharmacol 1990; 38:567-572.
9. Thelander L, Graslund A, Thelander M. Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem Biophys Res Commun 1983; 110:859-865.
10. Thelander L, Reichard P. Reduction of ribonucleotides. Annu Rev Biochem 1979; 48:133-158.
11. Ali AS, Ali S, El-Rayes BF, Philip PA, Sarkar FH. Exploitation of protein kinase C: a useful target for cancer therapy. Cancer Treat Rev 2009; 35:1-8.
12. Wang LM, Kucera GL. Deoxycytidine kinase is phosphorylated in vitro by protein kinase C alpha. Biochim Biophys Acta 1994; 1224:161-167.
13. Smal C, Vertommen D, Bertrand L, Ntamashimikiro S, Rider MH, Van Den Neste E, Bontemps F. Identification of in vivo phosphorylation sites on human deoxycytidine kinase. Role of Ser-74 in the control of enzyme activity. J Biol Chem 2006; 281:4887-4893.
14. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54:357-361.
15. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 1989; 58:137-171.
16. Bergman AM, Pinedo HM, Talianidis I, Veerman G, LovesWJP, Van derWilt CL, Peters GJ. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance associated protein overexpressing human cancer cell lines. Br J Cancer 2003; 88:1963-1970.
17. Ratnasinghe D, Phang JM, Yeh GC. Differential expression and activity of phosphatases and protein kinases in adriamycin sensitive and resistant human breast cancer MCF-7 cells. Int J Oncol 1998; 13:79-84.
18. Beck J, Bohnet B, Brugger D, Bader P, Dietl J, Scheper RJ, et al. Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with mdr1, MRP and LRP gene expression. Br J Cancer 1998; 77:87-91.
19. Clavy JS, Horwitz SB, Orr GA. Identification of the in vivo phosphorylation sites for acidic-directed kinases in murine mdr1b P-glycoprotein. J Biol Chem 1997; 272:5909-5914.
20. Ma L, Krishnamachary N, Center MS. Phosphorylation of the multidrug resistance associated protein gene encoded protein P190. Biochem 1995; 34:3338-3343.
21. Smith CD, Zilfou JT. Circumvention of P-glycoprotein mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. J Biol Chem 1995; 270:28145-28152.
22. Utz I, Spitaler M, Rybczynska M, Ludescher C, Hilbe W, Regenass U, et al. Reversal of multidrug resistance by the staurosporine derivatives CGP 41 251 and CGP 42 700. Int J Cancer 1998; 77:64-69.
23. Sedlak J, Hunakova L, Sulikova M, Chorvath B. Protein kinase inhibitorinduced alterations of drug uptake, cell cycle and surface antigen expression in human multidrug resistant (P-gP and MRP) promyelocytic leukemia HL-60 cells. Leuk Res 1997; 21:449-458.
24. Beltran PJ, Fan D, Fidler IJ, O'Brian CA. Chemosensitization of cancer cells by staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation. Biochem Pharm 1997; 53:245-247.
25. Killion JJ, Beltran P, O'Brian CA, Yoon SS, Fan D,Wilson MR, Fidler IJ. The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251. Oncol Res 1995; 7:453-459.
26. Monks A, Harris ED, Vaigro-Wolff A, Hose CD, Connely JW, Sausville EA. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. Invest New Drugs 2000; 18:95-107.
27. Ali S, Aranha O, Li Y, Pettit GR, Sarkar FH, Philip PA. Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1. Cancer Chemother Pharmacol 2003; 52:235-246.
28. Elgie AW, Sargent JM, Alton P, Peters GJ, Noordhuis P, Williamson CJ, Taylor CG. Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML. Leuk Res 1998; 22:373-378.
29. Grant S, Turner AJ, Bartimole TM, Nelms PA, Joe VC, Jarvis WD. Modulation of 1-(b-D-arabinofuranosyl) cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C. Oncol Res 1994; 6:87-99.
30. Kuiper CM, Broxterman HJ, Baas F, Schuurhuis GJ, Haisma HJ, Scheffer GL, et al. Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin. J Cell Pharmacol 1991; 1:35-41.
31. Keizer HG, Schuurhuis GJ, Broxterman HJ, Lankelma J, Schoonen WG, Van Rijn J, et al. Correlation of multidrug sensitive with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res 1989; 49:2888-2993.
32. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New calorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 1990; 82:1107-1112.
33. Keepers YP, Pizao PE, Peters GJ, Van Ark-Otte J,Winograd B, Pinedo HM. Comparison of the Sulforhodamine B Protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 1991; 27:897-900.
34. Peters GJ, Wets M, Keepers YP, Oskam R, Van Ark-Otte J, Noordhuis P, et al. Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int J Cancer 1993; 54:450-455.
35. Webb JL. Effect of more than one inhibitor. In: Webb JL, editor. Enzymes and metabolic inhibitors. Vol.1. New York: Academic Press; 1963. pp. 66-79. 487-512.
36. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47:331-384.
37. Peters GJ, Van der Wilt CL, Van Moorsel CJA, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000; 87:227-253.
38. Elion GB, Singer S, Hitchings GH. Antagonists of nucleic acid derivatives: Part VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem 1954; 208:477-488.
39. Lopez-Lopez R, Langeveld CH, Pizao PE, Van Rijswijk REN, Wagstaff J, Pinedo HM, Peters GJ. Effect of suramin on adenylate cyclase and protein kinase C. Anti-Cancer Drug Design 1994; 9:279-290.
40. Ruiz van Haperen VWT, Veerman G, Braakhuis BJM, Vermorken JB, Boven E, Leyva A, Peters GJ. Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts. Eur J Cancer 1993; 29A:2132-2137.
41. Bradford M. A rapid and sensitive method for the qualification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
42. Eriksson S, Kierdaszuk B, Munch-Petersen B, Oberg B, Johansson NG. Comparison of the substrate specifities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Comm 1991; 176:586-592.
43. Hatzis P, Al-Madhoon AS, Jü llig M, Petrakis TG, Eriksson S, Talianidis I. The intracellular localization of deoxycytidine kinase. J Biol Chem 1998; 273:30239-30243.
44. Hunakova L, Sulikova M, Duraj J, Sedlak J, Chorvath B. Stimulation of 1-(beta-D-arabinofuranosyl)cytosine (araC)-induced apoptosis in the multidrug resistant human promyelocytic leukemia cell lines with protein kinase inhibitors. Neoplasma 1996; 43:291-295.
45. Freund A, Boos J, Harkin S, Schulze-Mosgau M, Veerman G, Peters GJ, Gesher A. Augmentation of 1-b-D-arabinofuranosylcytosine (ara-C) ytotoxicity in leukemia cells by co-administration with antisignalling drugs. Eur J Cancer 1998; 34:805-901.
46. Spasokoukotskaya T, Csapo Z, Sasvari-Szekely M, Virga S, Talianidis I, Eriksson S, Staub M. Effect of phosphorylation on deoxycytidine kinase activity. Adv Exp Med Biol 2000; 486:281-285.
47. Chang ZF, Huang DY, Hsue NC. Differential phosphorylation of thymidine kinase in proliferating and M phase-arrested human cells. J Biol Chem 1994; 269:21249-21254.
48. Yamasaki F, Hama S, Yoshioka H, Kajiwara Y, Yahara K, Sugiyama K, et al. Staurosporine-induced apoptosis is independent of p16 and p21 and achieved via arrest at G2/M and at G1 in U251MG human glioma cell line. Cancer Chemother Pharmacol 2003; 51:271-283.
49. Ha MW, Hou KZ, Liu YP, Yuan Y. Effect of staurosporine on cycle of human gastric cancer cells. World J Gastroenterol 2004; 10:161-166.
50. Sigmond J, Peters GJ. Pyrimidine and purine analogues, effects on cell cycle regulation and the role of cell cycle inhibitors to enhance their cytotoxicity. Nucleosides Nucleotides Nucleic Acid 2004; 24:1997-2022.
51. Harmalkar MN, Shirsat NV. Staurosporine-induced growth inhibition of glioma cells is accompanied by altered expression of cyclins, CDKs and CDK inhibitors. Neurochem Res 2006; 31:685-692.
52. Shimizu T, Takahashi N, Tachibana K, Takeda K. Complex regulation of CDK2 and G1 arrest during neuronal differentiation of human prostatic cancer TSU-Prl cells by staurosporine. Anticancer Res 2001; 21:893-898.
53. Schnier JB, Nishi K, Goodrich DW, Bradbury EM. G1 arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. Proc Natl Acad Sci U S A 1996; 93:5941-5946.
54. Sigmond J, Todorova B, Smid K, Peters GJ. Cell cycle modulation enhances the cytotoxicity of thymidylate synthase inhibitors. Pteridines 2009; 20:128-136.